These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36642232)

  • 21. Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events.
    Chu HY; Jain R; Xie H; Pottinger P; Fredricks DN
    BMC Infect Dis; 2013 Feb; 13():105. PubMed ID: 23442261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients--an evidence-based approach.
    Karthaus M; Lehrnbecher T; Lipp HP; Kluge S; Buchheidt D
    Ann Hematol; 2015 Apr; 94(4):547-56. PubMed ID: 25697592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Utility of voriconazole therapeutic drug monitoring: a meta-analysis.
    Luong ML; Al-Dabbagh M; Groll AH; Racil Z; Nannya Y; Mitsani D; Husain S
    J Antimicrob Chemother; 2016 Jul; 71(7):1786-99. PubMed ID: 27165788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of dose adaptations following voriconazole therapeutic drug monitoring in pediatric patients.
    Lempers VJ; Meuwese E; Mavinkurve-Groothuis AM; Henriet S; van der Sluis IM; Hanff LM; Warris A; Koch BCP; Brüggemann RJ
    Med Mycol; 2019 Nov; 57(8):937-943. PubMed ID: 30759261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical usefulness of therapeutic drug monitoring of voriconazole in a university hospital.
    Cabral-Galeano E; Ruiz-Camps I; Len-Abad O; Pou-Clavé L; Sordé-Masip R; Meije-Castillo Y; Blanco-Grau A; Barba-Suñol P; Monforte-Torres V; Román-Broto A; Pahissa-Berga A; Gavaldà-Santapau J
    Enferm Infecc Microbiol Clin; 2015 May; 33(5):298-302. PubMed ID: 25459191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Voriconazole: an audit of hospital-based dosing and monitoring and evaluation of the predictive performance of a dose-prediction software package.
    Chaudhri K; Stocker SL; Williams KM; McLeay RC; Marriott DJE; Di Tanna GL; Day RO; Carland JE
    J Antimicrob Chemother; 2020 Jul; 75(7):1981-1984. PubMed ID: 32277819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
    Maertens JA; Raad II; Marr KA; Patterson TF; Kontoyiannis DP; Cornely OA; Bow EJ; Rahav G; Neofytos D; Aoun M; Baddley JW; Giladi M; Heinz WJ; Herbrecht R; Hope W; Karthaus M; Lee DG; Lortholary O; Morrison VA; Oren I; Selleslag D; Shoham S; Thompson GR; Lee M; Maher RM; Schmitt-Hoffmann AH; Zeiher B; Ullmann AJ
    Lancet; 2016 Feb; 387(10020):760-9. PubMed ID: 26684607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Comparison of Isavuconazole and Voriconazole in Terms of the Need for Dosage Adjustments Guided by Clinical Pharmacological Advice During Primary Prophylaxis of Invasive Fungal Infections in Pediatric Patients with Hemato-Oncological Malignancies.
    Gatti M; Campoli C; Belotti T; Cojutti PG; Masetti R; Pession A; Viale P; Pea F
    Ther Drug Monit; 2022 Oct; 44(5):641-650. PubMed ID: 35344524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients.
    Bartelink IH; Wolfs T; Jonker M; de Waal M; Egberts TC; Ververs TT; Boelens JJ; Bierings M
    Antimicrob Agents Chemother; 2013 Jan; 57(1):235-40. PubMed ID: 23114771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Clinical Significance of Voriconazole Therapeutic Drug Monitoring in Children With Invasive Fungal Infections.
    Kang HM; Lee HJ; Cho EY; Yu KS; Lee H; Lee JW; Kang HJ; Park KD; Shin HY; Choi EH
    Pediatr Hematol Oncol; 2015; 32(8):557-67. PubMed ID: 26558811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating a voriconazole dose modification guideline to optimize dosing in patients with hematologic malignancies.
    Perreault S; McManus D; Anderson A; Lin T; Ruggero M; Topal JE
    J Oncol Pharm Pract; 2019 Sep; 25(6):1305-1311. PubMed ID: 29996736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study.
    Yi WM; Schoeppler KE; Jaeger J; Mueller SW; MacLaren R; Fish DN; Kiser TH
    Ann Clin Microbiol Antimicrob; 2017 Sep; 16(1):60. PubMed ID: 28893246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Voriconazole concentrations and outcome of invasive fungal infections.
    Miyakis S; van Hal SJ; Ray J; Marriott D
    Clin Microbiol Infect; 2010 Jul; 16(7):927-33. PubMed ID: 19845698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data.
    Matsumoto K; Abematsu K; Shigemi A; Kanazawa N; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
    J Chemother; 2016 Jun; 28(3):198-202. PubMed ID: 26187373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, Efficacy, and Exposure-Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis.
    Martin JM; Macias-Parra M; Mudry P; Conte U; Yan JL; Liu P; Capparella MR; Aram JA
    Pediatr Infect Dis J; 2017 Jan; 36(1):e1-e13. PubMed ID: 27636722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a therapeutic drug-monitoring algorithm for outpatients receiving voriconazole: A multicentre retrospective study.
    Kato H; Umemura T; Hagihara M; Shiota A; Asai N; Hamada Y; Mikamo H; Iwamoto T
    Br J Clin Pharmacol; 2024 May; 90(5):1222-1230. PubMed ID: 38320604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers.
    Cojutti P; Candoni A; Forghieri F; Isola M; Zannier ME; Bigliardi S; Luppi M; Fanin R; Pea F
    Basic Clin Pharmacol Toxicol; 2016 Jun; 118(6):474-9. PubMed ID: 26572687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.
    Stott KE; Hope WW
    J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i12-i18. PubMed ID: 28355463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Voriconazole-induced psychosis in rhino-orbital invasive aspergillosis.
    Rekha HS; Paramasivam S; Raja K; Bharadwaj B
    BMJ Case Rep; 2023 Oct; 16(10):. PubMed ID: 37821144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinician ordering practices for voriconazole therapeutic drug monitoring: experiences of a referral laboratory.
    Miyakis S; van Hal SJ; Solvag CJ; Ray J; Marriott D
    Ther Drug Monit; 2010 Oct; 32(5):661-4. PubMed ID: 20720520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.